Over the last 20 years, some 100 biopharmaceuticals have gained marketing authorization in Europe, USA and other world regions. All biopharmaceu- tical products currently approved within the EU are protein-based. The majority of the first generation products were either unmodified monoclonal antibodies or proteins used clinically to either replace or augment levels of native human proteins. With the recent advances in genomics, proteomics, pharmaceutical target validation, and lead compound identification new perspectives of bio- pharmaceutical products development emerged. Protein engineering has recently facilitated the rational development of a number of proteins displaying an altered pharmacokinetics, biodistribution and therapeutic properties. New strategies and challenges in biopharmaceuticals developments yielded the second generation of protein drugs.
Operational Program Digital Poland, 2014-2020, Measure 2.3: Digital accessibility and usefulness of public sector information; funds from the European Regional Development Fund and national co-financing from the state budget.
Mar 31, 2020
Mar 30, 2020
|Nowe leki otrzymywane przy udziale technologii rekombinowanego DNA||Mar 31, 2020|
Godawska, Anna Kieć-Kononowicz, Katarzyna
Latacz, Gniewomir Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Godawska, Anna Pękala, Elżbieta Kieć-Kononowicz, Katarzyna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Nowak, Jacek K.
Institute of Bioorganic Chemistry PAS Committee on Biotechnology PAS